Cargando…

Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK

Influenza vaccine effectiveness (IVE) assessment is increasingly stratified by vaccine type or brand, such as done by the European network of DRIVE. In 2019/2020, eleven influenza vaccines were licensed in Europe. If more than one vaccine type is recommended or if more than one vaccine brand is avai...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuurman, Anke L., Ciampini, Sara, Vannacci, Alfredo, Bella, Antonino, Rizzo, Caterina, Muñoz-Quiles, Cintia, Pandolfi, Elisabetta, Liyanage, Harshana, Haag, Mendel, Redlberger-Fritz, Monika, Bonaiuti, Roberto, Beutels, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205138/
https://www.ncbi.nlm.nih.gov/pubmed/34129638
http://dx.doi.org/10.1371/journal.pone.0252836
_version_ 1783708449289273344
author Stuurman, Anke L.
Ciampini, Sara
Vannacci, Alfredo
Bella, Antonino
Rizzo, Caterina
Muñoz-Quiles, Cintia
Pandolfi, Elisabetta
Liyanage, Harshana
Haag, Mendel
Redlberger-Fritz, Monika
Bonaiuti, Roberto
Beutels, Philippe
author_facet Stuurman, Anke L.
Ciampini, Sara
Vannacci, Alfredo
Bella, Antonino
Rizzo, Caterina
Muñoz-Quiles, Cintia
Pandolfi, Elisabetta
Liyanage, Harshana
Haag, Mendel
Redlberger-Fritz, Monika
Bonaiuti, Roberto
Beutels, Philippe
author_sort Stuurman, Anke L.
collection PubMed
description Influenza vaccine effectiveness (IVE) assessment is increasingly stratified by vaccine type or brand, such as done by the European network of DRIVE. In 2019/2020, eleven influenza vaccines were licensed in Europe. If more than one vaccine type is recommended or if more than one vaccine brand is available for a specific risk group, it is not clear which factors affect the choice of a specific vaccine (type or brand) by a health practitioner for individual patients. This is important for IVE assessment. A survey tailored to the 2019/20 local vaccine recommendations was conducted among GPs in four European countries (Austria, Italy, Spain, UK) to understand how influenza vaccine is offered to recommended risk groups and, if GPs have a choice between 2 or more vaccines, what factors influence their vaccine choice for patients. Overall, 360 GPs participated. In Austria, Italy and Spain GPs indicated that influenza vaccines are commonly offered when patients present for consultation, whereas in the UK all GPs indicated that all relevant patients are contacted by letter. In Austria and Italy, roughly 80% of GPs had only one vaccine type available for patients <65y. The use of any specific vaccine type in this age group is mostly determined by the availability of specific vaccine type(s) at the clinic. GPs frequently reported availability of more than one vaccine type for patients ≥65y in Austria (45%), Italy (70%) and Spain (79%). In this group, patient characteristics played a role in choice of vaccine, notably older age and presence of (multiple) comorbidities. Knowing that a non-patient related factor usually determines the vaccine type a patient receives in settings where more than one vaccine type is recommended for risk groups <65y, simplifies IVE assessment in this age group. However, patient characteristics need careful consideration when assessing IVE in those ≥65y.
format Online
Article
Text
id pubmed-8205138
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82051382021-06-29 Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK Stuurman, Anke L. Ciampini, Sara Vannacci, Alfredo Bella, Antonino Rizzo, Caterina Muñoz-Quiles, Cintia Pandolfi, Elisabetta Liyanage, Harshana Haag, Mendel Redlberger-Fritz, Monika Bonaiuti, Roberto Beutels, Philippe PLoS One Research Article Influenza vaccine effectiveness (IVE) assessment is increasingly stratified by vaccine type or brand, such as done by the European network of DRIVE. In 2019/2020, eleven influenza vaccines were licensed in Europe. If more than one vaccine type is recommended or if more than one vaccine brand is available for a specific risk group, it is not clear which factors affect the choice of a specific vaccine (type or brand) by a health practitioner for individual patients. This is important for IVE assessment. A survey tailored to the 2019/20 local vaccine recommendations was conducted among GPs in four European countries (Austria, Italy, Spain, UK) to understand how influenza vaccine is offered to recommended risk groups and, if GPs have a choice between 2 or more vaccines, what factors influence their vaccine choice for patients. Overall, 360 GPs participated. In Austria, Italy and Spain GPs indicated that influenza vaccines are commonly offered when patients present for consultation, whereas in the UK all GPs indicated that all relevant patients are contacted by letter. In Austria and Italy, roughly 80% of GPs had only one vaccine type available for patients <65y. The use of any specific vaccine type in this age group is mostly determined by the availability of specific vaccine type(s) at the clinic. GPs frequently reported availability of more than one vaccine type for patients ≥65y in Austria (45%), Italy (70%) and Spain (79%). In this group, patient characteristics played a role in choice of vaccine, notably older age and presence of (multiple) comorbidities. Knowing that a non-patient related factor usually determines the vaccine type a patient receives in settings where more than one vaccine type is recommended for risk groups <65y, simplifies IVE assessment in this age group. However, patient characteristics need careful consideration when assessing IVE in those ≥65y. Public Library of Science 2021-06-15 /pmc/articles/PMC8205138/ /pubmed/34129638 http://dx.doi.org/10.1371/journal.pone.0252836 Text en © 2021 Stuurman et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Stuurman, Anke L.
Ciampini, Sara
Vannacci, Alfredo
Bella, Antonino
Rizzo, Caterina
Muñoz-Quiles, Cintia
Pandolfi, Elisabetta
Liyanage, Harshana
Haag, Mendel
Redlberger-Fritz, Monika
Bonaiuti, Roberto
Beutels, Philippe
Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK
title Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK
title_full Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK
title_fullStr Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK
title_full_unstemmed Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK
title_short Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK
title_sort factors driving choices between types and brands of influenza vaccines in general practice in austria, italy, spain and the uk
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205138/
https://www.ncbi.nlm.nih.gov/pubmed/34129638
http://dx.doi.org/10.1371/journal.pone.0252836
work_keys_str_mv AT stuurmanankel factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT ciampinisara factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT vannaccialfredo factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT bellaantonino factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT rizzocaterina factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT munozquilescintia factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT pandolfielisabetta factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT liyanageharshana factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT haagmendel factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT redlbergerfritzmonika factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT bonaiutiroberto factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk
AT beutelsphilippe factorsdrivingchoicesbetweentypesandbrandsofinfluenzavaccinesingeneralpracticeinaustriaitalyspainandtheuk